About: Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
Creator	Rossi, Francesco Bartoletti, Michele Angelo, D Bergamaschi, Luca Biffi, Mauro Concetta D'angelo, Emanuela Cosmi, Benilde Donati, Francesco Galié, Nazzareno Giannella, Maddalena Ialenti, Armando Paolisso, Pasquale Pascale, Renato Pizzi, Carmine Squadrito, Francesco Tedeschi, Sara Tesini, Giulia Viale, Pierluigi
source	Medline; PMC
abstract	BACKGROUND: Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized patients. METHODS AND RESULTS: Retrospective study of 450 laboratory-confirmed COVID-19 patients admitted to Sant’Orsola Bologna Hospital from March 01 to April 10, 2020. Clinical, laboratory and treatment data were collected and analyzed. The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared. Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40–60 mg twice daily) for 7 days. No significant differences in the main demographic characteristics and laboratory testings at admission were observed in the two heparin regimen subgroups, except for older age and prevalence of hypertension in the group treated with “standard” prophylaxis LMWH dosage. The intermediate LMWH administration was associated with a lower in-hospital all-cause mortality compared to the “standard” prophylactic LMWH dosage (18.8% vs. 5.8%, p = 0.02). This difference remained significant after adjustment with the propensity score for variables that differed significantly between the dosage groups (OR= 0.260, 95% CI 0.089–0.758, p=0.014). CONCLUSIONS: Intermediate LMWH dosage seems to be associated with lower incidence of mortality compared to standard DVT prophylaxys in hospitalized COVID-19 patients. Our study paves the way to further pathophysiological investigations and controlled studies of anticoagulation therapy in Covid-19 disease.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.3389/fphar.2020.01124
bibo:pmid	32848743
has license	cc-by
sha1sum (hex)	c33fa1e7c7ee07ca846617087c630560d63f65b2
schema:url	https://doi.org/10.3389/fphar.2020.01124
resource representing a document's title	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
has PubMed Central identifier	PMC7424043
has PubMed identifier	32848743
schema:publication	Front Pharmacol
resource representing a document's body	covid:c33fa1e7c7ee07ca846617087c630560d63f65b2#body_text
is schema:about of	named entity 'HOSPITALIZED PATIENTS' named entity 'EFFICACY' named entity 'HEPARIN' named entity 'MORTALITY' named entity 'DOSAGE' named entity 'COVID-19' named entity 'Low Molecular Weight Heparin' named entity 'ICU' named entity 'inflammatory condition' named entity 'prognosis' named entity 'inflammatory disorders' named entity 'heparin' named entity 'virus' named entity 'atrial fibrillation' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'prophylactic' named entity 'Pulmonary thrombosis' named entity 'LMWH' named entity 'heparin' named entity 'COVID' named entity 'thrombocytopenia' named entity 'Tocilizumab' named entity 'COVID' named entity 'LMWH' named entity 'infection' named entity 'IL-8' named entity 'all-cause' named entity 'venous thromboembolic disease' named entity 'ICU' named entity 'extracorporeal membrane oxygenation' named entity 'hematomas' named entity 'tropism' named entity 'clinical indication' named entity 'heart rate' named entity 'LMWH' named entity 'COVID' named entity 'infection' named entity 'anticoagulation' named entity 'arterial partial pressure of oxygen' named entity 'myocarditis' named entity 'COVID' named entity 'renal failure' named entity 'upper respiratory tract' named entity 'cardiovascular complications' named entity 'enoxaparin' named entity 'all-cause mortality' named entity 'Coagulopathy' named entity 'clinical evidence' named entity 'tocilizumab' named entity 'respiratory failure' named entity 'AKI' named entity 'older age' named entity 'anti-thrombotic' named entity 'attending physician' named entity 'LMWH' named entity 'LMWH' named entity 'prophylaxis' named entity 'hypercoagulation' named entity 'intubation' named entity 'anticoagulant' named entity 'COVID 19' named entity 'confounder' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software